Replies to post #132993 on Biotech Values

[oc631]

The encouraging part for me was the fact that response was seen with durability also in uninjected lesions including visceral sites.

This caught my eye also. Obviously the herpes virus works as an unintended vector somewhat like the adenovirus. If Amgen does see similar results to their phase 2 program they could have a blockbuster drug on their hands. OncoVex has a good safety profile, is completely novel showing strong efficacy compared to other developers in the oncolytic virus space, and could be used in expanded indications.

Does anyone know how long this engineered virus can live within the patients body? What excites me about using the herpes virus are the characteristics that allow it to hide from the immune system. If an engineered virus could lay dormant in a patients body until triggered by cancer tumor growth Amgen could be on its way to finding a cure for cancer.